Ahmad Dawalibi

Dr. Ahmad Dawalibi

Biomedical and Translational Sciences, Sanford School of Medicine, University of South Dakota, Vermillion, South Dakota, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ADAhmad Dawalibi
Ahmad Dawalibi
AAAmal Ahmed Alosaimi
Amal Ahmed Alosaimi
Khalid MohammadKhalid Mohammad
Khalid Mohammad
Bone metastases, a common and debilitating consequence of advanced cancers, involve a complex interplay between malignant cells and the bone microenvironment. Central to this interaction are interleukins (ILs), a group of cytokines with critical roles in immune modulation and inflammation. This review explores the dualistic nature of pro-inflammatory and anti-inflammatory interleukins in bone metastases, emphasizing their molecular mechanisms, pathological impacts, and therapeutic potential. Pro-inflammatory interleukins, such as IL-1, IL-6, and IL-8, have been identified as key drivers in promoting osteoclastogenesis, tumor proliferation, and angiogenesis. These cytokines create a favorable environment for cancer cell survival and bone degradation, contributing to the progression of metastatic lesions. Conversely, anti-inflammatory interleukins, including IL-4, IL-10, and IL-13, exhibit protective roles by modulating immune responses and inhibiting osteoclast activity. Understanding these opposing effects is crucial for developing targeted therapies aimed at disrupting the pathological processes in bone metastases. Key signaling pathways, including NF-κB, JAK/STAT, and MAPK, mediate the actions of these interleukins, influencing tumor cell survival, immune cell recruitment, and bone remodeling. Targeting these pathways presents promising therapeutic avenues. Current treatment strategies, such as the use of denosumab, tocilizumab, and emerging agents like bimekizumab and ANV419, highlight the potential of interleukin-targeted therapies in mitigating bone metastases. However, challenges such as therapeutic resistance, side effects, and long-term efficacy remain significant hurdles. This review also addresses the potential of interleukins as diagnostic and prognostic biomarkers, offering insights into patient stratification and personalized treatment approaches. Interleukins have multifaceted roles that depend on the context, including the environment, cell types, and cellular interactions. Despite substantial progress, gaps in research persist, particularly regarding the precise mechanisms by which interleukins influence the bone metastatic niche and their broader clinical implications. While not exhaustive, this overview underscores the critical roles of interleukins in bone metastases and highlights the need for continued research to fully elucidate their complex interactions and therapeutic potential. Addressing these gaps will be essential for advancing our understanding and treatment of bone metastases in cancer patients.

2 May 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MBMohamad Bakir
Mohamad Bakir
ADAhmad Dawalibi
Ahmad Dawalibi
MMMohammad Alaa Mufti
Mohammad Alaa Mufti
ABAyman Behiery
Ayman Behiery
Khalid MohammadKhalid Mohammad
Khalid Mohammad
Bone metastases are a prevalent and debilitating consequence of various cancers, including breast and prostate carcinomas, which significantly compromise patient quality of life due to pain, fractures, and other skeletal-related events (SREs). This review examines the pathophysiology of bone metastases, emphasizing the role of the bone microenvironment in tumor progression through mechanisms such as osteotropism and the dysregulated bone remodeling cycle. The primary focus is on the emerging nano-drug delivery systems (DDS) designed to target the bone microenvironment and improve the therapeutic index of anticancer agents. Current treatments, mainly comprising bisphosphonates and radiotherapy, provide palliative benefits but often have limited efficacy and significant side effects. Innovative strategies, such as bisphosphonate-conjugated nanoparticles and targeted therapies that utilize the unique bone marrow niche, are explored for their potential to enhance drug accumulation at metastatic sites while minimizing systemic toxicity. These approaches include the use of liposomes, polymeric nanoparticles, and inorganic nanoparticles, which can be functionalized to exploit the biological barriers within the bone microenvironment. This review also discusses the challenges and future directions for nano-DDS in clinical settings, emphasizing the need for multidisciplinary research to effectively integrate these technologies into standard care protocols.

12 September 2022 in International Journal of Angiology
Verified
Journal Article
Closed access
PDF file
ADAhmad Dawalibi
Ahmad Dawalibi
MMMuhammad Atif Mazhar
Muhammad Atif Mazhar
Sadia QaziSadia Qazi
Sadia Qazi
PGPaul Ganguly
Paul Ganguly
ABAyman Behiery
Ayman Behiery
Anatomy is a vital basic science for safe and effective medical practice and its significance increases several folds when it is taught in a clinically relevant manner. In today's time-compressed modern medical curricula, the importance of dissection-based anatomy programs is integral to teaching–learning outcome. Sound anatomical knowledge is critical to safe clinical and surgical practice as it is fundamental to the career of future doctors. In this pictorial essay, we present a case of a left ectopic pelvic kidney during one of the faculty-guided dissection sessions at the Alfaisal University. Such an anomaly motivated students to perform further meticulous dissection and to engage in detailed discussions after identifying associated abnormal findings. It is believed that these practices at the very start of the medical journey of students will effectively enhance their clinical reasoning skills by integrating basic and clinical anatomy.